Central nervous system (CNS) and psychiatric disorders, including depression, schizophrenia, bipolar disorder, and neurodegenerative conditions, continue to represent a significant global health burden. Although effective treatments are available, medication non-adherence remains a major challenge that can limit real-world outcomes.
Many patients with psychiatric and neurological conditions do not consistently follow prescribed treatment plans, which can lead to relapse, disease progression, and increased healthcare utilisation.
According to the World Health Organization, nearly 50% of patients with chronic disease do not take medication as prescribed. In CNS and psychiatric therapies, medication adherence is often hindered by cognitive impairment, swallowing difficulties, and the need for long-term treatment.
As the industry shifts toward patient-centric drug development, there is growing interest in dosage forms that better support patient needs. Orally disintegrating tablets (ODTs) are emerging as a practical solution by simplifying administration and helping address adherence-related barriers in CNS drug delivery.
Delivering effective pharmacotherapy in CNS and psychiatric disorders involves navigating a unique set of patient-related and treatment-related complexities. Unlike many other therapeutic areas, CNS conditions directly affect cognitive, behavioural, and physical functions. These factors play a critical role in how medications are administered and followed in real-world settings.
One of the most significant barriers to effective treatment is cognitive impairment. Patients with conditions such as schizophrenia and major depression often experience difficulties with:
These challenges make consistent medication adherence difficult.
Studies indexed by the National Institute of Health indicate that medication non-adherence in schizophrenia averages around 50%, with rates exceeding 60% in certain populations. This highlights the scale and persistence of the issue.
The economic burden is also considerable. In the United Kingdom, schizophrenia-related healthcare costs are estimated at approximately £400 million annually, with nearly 40% attributed to non-adherence. Treatment non-adherence is implicated as a significant driver of relapse and hospitalisation costs. This reflects both the clinical and financial impact of inconsistent treatment.
Swallowing difficulties are common among:
The prevalence of swallowing difficulties in patients taking antipsychotics has been reported to range from 21.9% to 69.5%. As a result, conventional oral dosage forms such as tablets and capsules can become a barrier to effective treatment, particularly in outpatient and home-care settings.
Read Our Blog On “Dysphagia & Medication Adherence: What We Need to Know”
Certain CNS conditions, including acute agitation and anxiety, require timely intervention. Delayed onset of action can limit effective symptom management, making faster-acting formulations increasingly important.
Taken together, these challenges highlight a broader limitation: Traditional drug delivery systems are not always aligned with the functional needs of CNS patients. This has led to an increasing emphasis on patient-centric formulation strategies that improve ease of administration, reduce treatment burden, and support better adherence.
As a result, the adoption of alternative dosage forms, particularly orally disintegrating formulations, is accelerating. These formulations are specifically designed to address many of the challenges associated with CNS drug delivery.
As the limitations of conventional oral dosage forms become increasingly evident in CNS therapies, orally disintegrating formulations, including ODTs, have emerged as a practical and patient-centric alternative.
These formulations are designed to:
From a clinical perspective, orally disintegrating formulations directly address several barriers observed in CNS patient populations.
Patients experiencing cognitive impairment or swallowing difficulties benefit from dosage forms that require minimal effort and reduce the likelihood of missed or incorrect dosing.
Beyond patient convenience, these formulations offer important advantages from a development and regulatory standpoint.
The U.S. Food and Drug Administration recognises ODTs as a distinct dosage form, defined by their ability to disintegrate within a short time frame when placed on the tongue. This regulatory clarity has supported their increasing adoption across multiple therapeutic areas, including CNS disorders.
The benefits of ODTs extend beyond clinical outcomes. From a business perspective, they offer:
These factors contribute not only to better real-world outcomes but also to stronger market positioning for pharmaceutical products.
The increasing use of orally disintegrating formulations in CNS and psychiatric therapies is supported by both clinical evidence and changing market demands. As healthcare continues to focus on improving real-world treatment outcomes, formulations that enhance adherence and simplify administration are gaining greater importance.
Research indexed by the National Institutes of Health (NIH) has consistently shown that simpler drug administration can improve patient compliance, particularly in CNS disorders where adherence challenges are common. Studies suggest that reducing dosing complexity can support treatment continuity, improve adherence, and contribute to better therapeutic outcomes.
Demand for orally disintegrating formulations continues to rise, especially within CNS therapies. The growing prevalence of neurological and psychiatric disorders, combined with an ageing population, is increasing the need for patient-friendly dosage forms.
At the same time, pharmaceutical companies are recognizing the strategic value of these formulations. Beyond improving patient experience, they offer opportunities for product differentiation and lifecycle management in competitive markets.
Together, clinical findings and market trends highlight the growing importance of orally disintegrating formulations in modern CNS therapies. As patient-centric healthcare continues to evolve, ODTs are becoming an increasingly valuable approach to improving treatment experience and supporting better long-term outcomes.
Orally disintegrating formulation tablets offer several benefits in CNS and psychiatric therapies by addressing common patient-related challenges and improving treatment experience.
Easy administration without water supports consistent dosing, particularly for patients with cognitive challenges or treatment reluctance.
Their convenient and non-invasive nature makes them suitable for elderly and psychiatric patients.
Rapid disintegration in the mouth eliminates the need to swallow whole tablets, improving accessibility.
ODTs support product differentiation, lifecycle management, and patient-centric drug development.
Overall, ODTs provide a practical solution that improves both patient experience and treatment delivery in CNS care.
The pharmaceutical industry is increasingly moving toward patient-centric drug development, where treatment success depends not only on clinical efficacy but also on how well therapies align with real-world patient needs. This shift is particularly important in CNS and psychiatric disorders, where medication adherence remains a major challenge with significant clinical and economic impact.
Research indexed by the National Institutes of Health (NIH) suggests that poor medication adherence contributes to nearly 10% of hospitalisations and results in an estimated $100-300 billion in avoidable healthcare costs annually. This highlights the growing need for treatment approaches that improve usability and support long-term adherence.
Regulatory bodies such as the U.S. Food and Drug Administration (FDA) have further reinforced this approach by encouraging patient-focused drug development. These initiatives emphasize the importance of designing therapies that are easier to use and better aligned with patient preferences.
In this context, orally disintegrating formulations represent a practical example of patient-centric drug delivery. By addressing challenges such as swallowing difficulties, complex administration, and treatment resistance, ODTs help improve ease of use and support better adherence in CNS patient populations.
This growing focus on patient-centric innovation reflects the need for formulations that balance clinical effectiveness with real-world usability, particularly in complex therapeutic areas such as CNS disorders.
As the industry moves toward more patient-centric and outcome-driven models, the role of orally disintegrating formulations in CNS therapies is set to expand. The rising burden of neurological and psychiatric disorders, along with increasing awareness of adherence challenges, is driving demand for more accessible dosage forms.
Advances in formulation science and excipient technologies are enabling more stable, scalable, and patient-friendly ODTs. At the same time, pharmaceutical companies are leveraging these formulations for lifecycle management and product differentiation in competitive markets.
With continued focus on improving real-world outcomes, ODTs are expected to play a growing role in CNS drug delivery. Efforts within NOVUMGEN are aligned with this direction, focusing on developing patient-centric formulations that balance clinical effectiveness with ease of use.
CNS and psychiatric disorders present significant treatment challenges, particularly due to factors such as cognitive impairment, swallowing difficulties, and poor adherence. These challenges often limit real-world treatment effectiveness despite available therapies.
Orally disintegrating formulations offer a practical solution by improving ease of administration, patient acceptability, and treatment continuity. Their increasing adoption reflects a broader shift toward patient-centric drug development.
As this shift continues, ODTs are likely to become an integral part of CNS therapy strategies, supporting better outcomes while addressing both clinical and real-world patient needs.